Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Oct 13, 2022 10:41pm
340 Views
Post# 35023999

RE:November 2022 Upcoming Report

RE:November 2022 Upcoming Report

RoseHeaven wrote: August 29, 2022 Report - # of Patients waiting for evaluation at each reporting stage 

1) 90 days - 7 patients 
2) 180 days - 4 patients
3) 270 days - 2 patients 
4) 360 days - 6 patients 
5) 450 days - 2 patients 

These are the patients likely to get evaluated and to be reported in November 2022 report. It is very likely that only 2 patients would be evaluated at 450 days by November 2022 report making the total number of evaluable patients 26, only 1 patient more than 25 patients TLT was aiming for BTD. 

If these 2 patients were evalauted as CR at 450 days (best case scenario), total CR pateints at 450 days to be 7 out of 26 evaluable patients brining CR to 27%.

I am expecting a big boots in CR at 360 days as 6 more patients would likely to have evaluated by November 2022 report.

Do you think 27% CR at 450 days is good enough for BTD?
Or TLT should wait for more patients to be evaluated at 450 days for BTD? 

Thanks

RH 

  



 

Quick answer....Yes.  

Merck set a relatively low bar at 19%, and in order for a patient to reach that low bar, he must undergo "systemic" treatment (with its associated side effects) every 3 weeks...for up to 24 months as long as there is no disease progression.  Such a treatment-intensive systemic treatment demands there be more patient-friendly & effective options....and both systemic & non-systemic (i.e. bladder instillation) options are what Urologists, the International Bladder Cancer Group & HHS/FDA are currently demanding.  

Imo, the minimum required CR% for FDA approval depends on the type of treatment given (systemic vs non-systemic).  Systemic treatments (like Keytruda) generally cause greater toxicity.  Therefore, the minimum CR% needed for an approval may be higher for such a treatment vs an intravesical option. Considering our ACT is a non-systemic option, one could argue the efficacy threshold for our approval could potentially be even lower than what Keytruda has already established....not saying that will be the case. 

All things considered, I'm feeling confident.  Good luck...


 

 

<< Previous
Bullboard Posts
Next >>